硼替佐米聯(lián)合沙利度胺地塞米松治療對多發(fā)性骨髓瘤患者炎癥指標(biāo)免疫功能的影響
Efficacy bortezomib,thalidomide and dexamethasone on patientswith multiple myeloma Zhu Ruifeng, Zhou Shuiyang, Bao Weiying, Wang Hengshi, Fan Lu, Wang Liping, Wang Xiaoyan. , , ,2O1699,
【Abstract】ObjectiveThe eficacy bortezomib,thalidomide,and dexamethasone in treating patients withmultiple myeloma was investigated.MethodsA total 10O multiple myeloma patientsadmited to District Central in between August 2O2O and August 2023 wereenrolld assubjects for this study.These patients were randomlyassigned into two groups (5O each) by a random number table.The control group received thalidomideand dexamethasone,whereas theobservation group was administered bortezomib inaddition tothecontrol group'sregimen.Theclinical eficacy,inflammationmarkers,immune function,bone metabolism indicators,and adverse reactions between the two groups were compared.ResultsThe observation group demonstrateda higheroverall clinical efective rate compared tothe control group,with astatistically significant difference (P<0.05) .Post-treatment levels vascular endothelial growth factor (VEGF), interleukin-6 (IL6),C-reactive protein (CRP), interleukin-17 (IL-17),T lymphocyte subset CD 8+ ,and type I collagen C-terminal peptide(CTX-I) were lower in the observation group than those in the control group.Conversely,CD 4+ ,CD 3+ , CD4+/CD8+ratios,osteocalcin (BGP),and alkaline phosphatase (ALP)levelswere higher,with all diferences being statistically significant( P <0.05).Adverse reactions between the two groups were comparable,with no statistically significant difference( P >0.05).ConclusionThecombineduse bortezomib with thalidomideand dexamethasoneinthe treatment multiplemyeloma patientsyieldssignificant therapeutic benefits,enhances immune function,reduces inflammatoryresponses,improvesbone metabolism,andexhibitsa high level safety.
【Key Words】Multiple myeloma;Dexamethasone;Bortezomib; Thalidomide; Inflammatory markers; Immu-nity
多發(fā)性骨髓瘤是一種惡性血液疾病,骨髓漿細(xì)胞惡性增殖是該病形成的主要原因,以骨痛、出血、腎功能不全、貧血等為臨床表現(xiàn),若控制不理想,會(huì)對機(jī)體內(nèi)其他組織、器官造成嚴(yán)重?fù)p傷,大大降低了患者生存質(zhì)量[12。(剩余5981字)
-
-
- 山西醫(yī)藥雜志
- 2025年02期
- 益腎活血方治療Ⅲ期糖尿病腎病患...
- 基于陰道內(nèi)測壓法的產(chǎn)后壓力性尿...
- 艾司洛爾 + 體外膜肺氧合治療...
- 硼替佐米聯(lián)合沙利度胺地塞米松治...
- 他克莫司與達(dá)格列凈聯(lián)合用藥對I...
- 重癥監(jiān)護(hù)病房老年心力衰竭患者心...
- 左心系統(tǒng)造影聯(lián)合心臟磁共振成像...
- 基于受試者工作特征曲線分析經(jīng)顱...
- CT及磁共振成像診斷縱隔型肺癌...
- 卡瑞利珠單抗聯(lián)合多西他賽及奈達(dá)...
- 喜炎平注射液輔助治療小兒肺炎的...
- 卡瑞利珠單抗聯(lián)合介入治療對肝癌...
- 沙庫巴曲纈沙坦聯(lián)合阿托伐他汀治...
- 超聲引導(dǎo)下星狀神經(jīng)節(jié)阻滯在胃癌...
- 關(guān)節(jié)鏡輔助下改良三聯(lián)術(shù)治療復(fù)發(fā)...
- 引導(dǎo)式教育護(hù)理聯(lián)合認(rèn)知行為療法...
- 責(zé)任小組制的三級質(zhì)控護(hù)理在胰腺...
- 基于危重病護(hù)理評分法引導(dǎo)的干預(yù)...
- 《山西醫(yī)藥雜志》第六屆編委會(huì)青...